# Utilizing Metabolomics to Identify Potential Biomarkers and Perturbed Metabolic Pathways in Osteoarthritis: A Systematic Review

<sup>1</sup>Peyton Van Pevenage, <sup>2</sup>Jaedyn T. Birchmier, and <sup>2,3,4</sup>Ronald K. June

#### **Corresponding Author**

Ronald K June II
Professor, Mechanical & Industrial Engineering
Montana State University
PO Box 173800
Bozeman, MT 59717-3800
rjune@me.montana.edu
406.994.2203 (tel)
406.994.6292 (fax)

**Keywords:** osteoarthritis, biomarkers, metabolomics, metabolism

<sup>&</sup>lt;sup>1</sup>University of Washington School of Medicine, Seattle, Washington, United States

<sup>&</sup>lt;sup>2</sup>Department of Mechanical & Industrial Engineering, Montana State University

<sup>&</sup>lt;sup>3</sup>Department of Microbiology & Cell Biology, Montana State University

<sup>&</sup>lt;sup>4</sup>Department of Orthopaedics and Sports Medicine, University of Washington

#### **Abstract**

**Purpose**: Osteoarthritis (OA) is a joint disease that is clinically diagnosed using components of history, physical exam, and radiographic evidence of joint space narrowing. Currently, there are no laboratory findings that are specific to a diagnosis of OA. The purpose of this systematic review is to evaluate the state of current studies of metabolomic biomarkers that can aid in the diagnosis and treatment of OA.

**Methods**: Articles were gathered from PubMed and Web of Science using the search terms "osteoarthritis" and "biomarkers" and "metabolomics". Last search of databases took place July 20<sup>th</sup>, 2021. Duplicates were manually screened, along with any other results that were not original journal articles. Only original reports involving populations with diagnosed primary or secondary OA (human participants) or surgically induced OA (animal participants) and a healthy control group for comparison were considered for inclusion. Metabolites and metabolic pathways reported in included articles were then manually extracted and evaluated for significance based on reported *a priori* p-values and/or area under the receiver-operator curve (AUC).

Results: Of the 129 results that were returned in the database searches, 36 unique articles met the inclusion criteria. Articles were categorized based on body fluid analyzed: 6 studies on urine samples, 12 studies on plasma samples, 9 studies on synovial fluid (SF) samples, 8 studies on serum samples, and 1 study that involved both plasma and synovial fluid. To synthesize results, individual metabolites, as well as metabolic pathways that involve frequently reported metabolites, are presented for each study. Indications as to whether metabolite levels were increased or decreased are also included if this data was included in the original articles.

Conclusions: These studies clearly show that there are a wide range of metabolic pathways perturbed in OA. For this period, there was no consensus on a single metabolite, or panel of metabolites, that would be clinically useful in early diagnosis of OA or distinguishing OA from a healthy control. However, many common metabolic pathways were identified in the studies, including TCA cycle, fatty acid metabolism, amino acid metabolism (notably BCAA metabolism and tryptophan metabolism via kynurenine pathway), nucleotide metabolism, urea cycle, cartilage metabolism, and phospholipid metabolism. Future research is needed to define effective clinical biomarkers of osteoarthritis from metabolomic and other data.

#### Introduction

Osteoarthritis (OA) is the most prevalent form of arthritis and has profound detrimental impacts on the patient population burdened by this disease. Approximately 54 million adults in the US have been diagnosed with some form of arthritis, with about 33 million of these being diagnosed with OA. Factors such as age, obesity, and injury, among many others, are involved in the development of OA; as the US population ages and rates of obesity are on the rise, the prevalence of OA is expected to increase as the total number of arthritis cases, which includes OA diagnoses, is predicted to rise to 78 million US adults by the year 2040. As OA negatively affects activity levels and quality of life for patients, it can be more difficult to control chronic conditions that OA patients may be concurrently facing, such as diabetes, hypertension, or mental health disorders. OA is also associated with an increased lifetime risk of developing heart disease by 50% as well as an increased all-cause mortality of 55%. 1.2 As there are no treatments or therapies currently FDA approved and available that can reverse the progression of OA, it is important to make the diagnosis early so that changes can be made to slow the progression and limit the associated negative impacts on quality of life and overall health of patients. Metabolomic profiling is an emerging technology that provides systemic insight into disease processes by characterizing large numbers of biochemical reactants and products, termed metabolite features. As such, there is great potential for using metabolomics to support improved and early diagnosis of OA. Development of metabolomic biomarkers of OA has further potential to identify novel targets for both therapeutic intervention and monitoring disease progression.

OA has historically been considered a degenerative disease, and its development and progression originally were attributed to "wear and tear". However, in recent decades our understanding of OA development has evolved to include chronic low-grade inflammation in addition to maladaptive signaling that activate a cascade of catabolic processes across multiple

tissues in the joint.<sup>4</sup> Ultimately in OA the homeostatic balance between maintenance and degradation is upset resulting in deterioration of bone and cartilage.<sup>4</sup> However the metabolic links between disrupted homeostasis and the pathogenesis of OA are not completely understood, and are an emerging topic of active research utilizing metabolomic analysis.<sup>3-5</sup> Metabolomics is a growing research field that characterizes large numbers of small-molecules using advanced technology. Metabolomic profiling provides insight into the myriad biochemical reactions that occur in cells and tissues, and pathologically-altered metabolites have the potential to serve as molecular biomarkers of disease processes. The objective of this review is to build upon prior knowledge<sup>6</sup> and address the current state of metabolomic biomarkers for OA.

The scope of this review includes metabolomic findings by H¹-NMR, various mass spectroscopy techniques, and immunosorbent assays related to primary and secondary OA. By performing a systematic review involving individual metabolites associated with OA and metabolic pathways that are perturbed in OA disease pathogenesis, this review will summarize both insight into OA provided by metabolomics and candidate biomarkers for future studies. The insight provided here may support and guide further research to enable earlier diagnosis of OA using metabolite biomarkers.

### <u>Methods</u>

The aim of this study was to perform a systematic review of the current state of published metabolomic attempts to discover biomarkers of osteoarthritis.<sup>7</sup> A search of PubMed and Web of Science was performed and included the search terms: "metabolomics" and "osteoarthritis" and "biomarkers". A table depicting the search terms for each database is given below in **Table**1. Included articles were published up until July 20<sup>th</sup>, 2021, with no specific start date filter. To ensure a broad range of studies, there were no filters used for species or language, although all results were in the English language. Initial results were then manually reviewed by PVP to

detect duplications. After duplicate articles were removed, the remaining articles were independently reviewed by PVP to remove any results that were not original refereed journal articles (*e.g.* conference proceedings) or did not meet the inclusion and exclusion criteria stated below. Reasons for excluding articles were noted and discussed between PVP and RKJ until a consensus was reached. The articles remaining to be included were then grouped based on body fluid utilized in the study: 12 studies of plasma, 6 studies of urine, 9 studies of synovial fluid (SF), 8 studies of serum, and one study of both SF and plasma.

**Table 1.** Search Strategy including search terms used for identifying articles in each database.

Database	Search Terms Used	Results
Searched		
PubMed	"osteoarthritis" AND	70
	"biomarkers" AND	
	"metabolomics"	
Web of Science	TS = ("osteoarthritis" AND	59
(advanced	"biomarkers" AND	
search)	"metabolomics")	

#### Inclusion and Exclusion Criteria

Only original journal articles were included in this review; reviews, abstracts, and brief reports were screened out. Articles were considered for inclusion only if the study population included a group with diagnosed primary or secondary OA (for studies of human participants) or surgically induced OA (for non-human subjects) and a healthy control to allow for comparison.

Publications were excluded if they (a) evaluated metabolites specific to therapeutic interventions

but did not identify baseline metabolomic profiles or (b) did not identify potential biomarkers of OA with statistical significance. For inclusion, articles also needed to include data describing the metabolomic baseline of healthy controls, or the metabolomics involved in osteoarthritic joints. Additional exclusion criteria included (a) evaluation of animal OA with a distinct pathogenesis differing from that of humans (i.e., OA in equine athletes arising specifically due to carpal osteochondral fragmentation). Articles also needed to include both measures of statistical significance for metabolites and predictive diagnostic value, including p-values or area under the receiver-operator curve (AUC). For metabolite features or pathways to be deemed significant they needed to reach an *a priori* significance threshold of p < 0.05 or AUC > 0.8.

#### Data Abstraction

After abstracts were screened using the inclusion and exclusion criteria mentioned, papers considered for inclusion were read in their entirety. Key metabolite features and metabolic pathways were manually extracted based on p-values below the *a priori* threshold of 0.05 or AUCs greater than 0.80. Additional data that was extracted from the articles included the name of first author, year published, body fluid sampled, method of metabolite analysis, and number of subjects in the groups studied. Metabolites that were identified as significant were then categorized according to the particular body fluid that was studied, and metabolites were further grouped based on metabolic pathway involved and biochemical classification. Key metabolic pathways were also categorized according to the body fluid sampled. Data extraction was performed independently by PVP and then reviewed with RKJ.

#### Result Synthesis

Eligibility for inclusion in data synthesis was determined based on if significant *a priori* or AUC values were included in the studies. Data from each study was manually extracted and

transferred into a Microsoft Excel. The data was then further synthesized by grouping key metabolites based on biochemical class metabolic pathway for each fluid type sampled. This allowed for evaluation of metabolic pathways that were perturbed and offers insight into pathogenesis of osteoarthritis as a disease. No methods were needed for data conversion or handling of missing summary statistics, as each study included *a priori* and/or AUC values for metabolites presented.

Tables were used to present the extracted metabolite and metabolic pathway. For each body fluid studied, a table was created; significant metabolite and metabolic pathway data extracted was then populated in a row in the table corresponding to the fluid evaluated in the study.


Grouping of results based on the fluid that was studied allowed for identification of replicated metabolites, as well as common metabolic pathways identified.

#### Bias Evaluation

Bias was analyzed at the study and fluid sample level. All disclaimers and statements of competing interest were evaluated. Patient recruitment/selection processes were evaluated; information, or lack thereof, on concurrent health conditions of patients were taken into consideration; targeted versus untargeted metabolomic analysis strategies were noted; finally, methods of acquiring fluid samples (*e.g.* clinical patient samples vs cadaver samples) were all taken into consideration. All results reported should be evaluated with the consideration that there are comorbidities that can confound systemic metabolomic attempts to identify biomarkers specific to OA in unknown ways, as the pathophysiologic link between OA and many health conditions have not been discovered or fully investigated.

#### **Results**

Using the search terms described above, 129 total articles were gathered from PubMed and Web of Science. After applying inclusion and exclusion criteria, 36 articles remained for this review. 46 excluded papers were duplicates between the search results of the two databases. 28 excluded results were not original articles and instead consisted of brief reports, reviews, abstracts, editorial material, and a textbook chapter. The 55 remaining articles were then analyzed to determine inclusion: 19 of these were excluded that were either not relevant to OA metabolomics or possible biomarkers, intended to evaluate therapeutic effects of herbal medicine for treatment of OA, evaluated metabolomics to predict responses to total joint replacements in OA, or analyzed metabolomics of OA in a species and disease model that was specific to the species and therefore not generalizable to OA in humans. The remaining 36 articles were included in the review as they offered insight into metabolomics of OA versus healthy controls (34 articles) or provided data on baseline healthy serum (1 article) and plasma (1 article) amino acid levels for reference (Figure 1).



**Figure 1:** Flow diagram of literature search performed on July 20, 2021, displaying the study selection process.

# **Study Characteristics**

Upon initial review of the articles, general characteristics of each study were extracted (**Table 2**). These data included the article author, specific body fluid that was used for metabolomic profiling, the model species, and the sample sizes of the various groups. This allowed for further categorization of metabolomic results into the fluids that were analyzed in the studies: plasma, urine, synovial fluid, and serum.

Table 2. Study characteristics

Article Author	Fluid	Model	Fluid Analysis	Sample size(s)
	Sampled	Species	Method	
Rockel et al., 2018 <sup>8</sup>	Plasma	Human	LC-MS/MS	OA=152, HC=194
Steventon et	Plasma	Human	RP-HPLC with	HC=100
al., 2012 <sup>9</sup>			fluorescence	
			detection	
Smilde et al.,	Urine	Guinea	H <sup>1</sup> NMR	OA=12, HC=6
200510		Pig		
Carlson et al.,	Synovial	Human	LC-MS	OA=5, HC=5
2018 <sup>11</sup>	Fluid			

Loeser et al.,	Urine	Human	H <sup>1</sup> NMR, ELISA,	OA1=22, OA2=22
2016 <sup>12</sup>			automated	
			immunoanalyzer	
Carlson et al.,	Synovial	Human	LC-MS	OA GI-II=55, OA GIII-
2019 <sup>13</sup>	Fluid			IV=17, HC=7
Thompson et	Serum	Human	FI-ESI-MS	OA=40
al., 2011 <sup>14</sup>				
Costello et al.,	Plasma	Human	UPLC-MS, FI-ESI-	OA=704
202015			MS	
Hu et al.,	Synovial	Rabbit	UPLC-MS	OA=12, HC=12
202016	Fluid			
Kang et al.,	Synovial	Human	UPLC-QTOF-MS	OA=10
2015 <sup>17</sup>	Fluid			
Jiang et al.,	Urine	Rat	GC-TOF-MS	OA=8, HC=8
2018 <sup>18</sup>				
Maher et al.,	Serum	Ovine	H <sup>1</sup> NMR	OAm=24, HC=12
2012 <sup>19</sup>				
Datta et al.,	Plasma	Mouse	RP-LC-MS-MS	n=undefined
2017 <sup>20</sup>				
Adams et al.,	Synovial	Human	LC-MS, GC-MS,	OA=20, HC=20
2014 <sup>21</sup>	Fluid		ELISA	
Huang et al.,	Plasma	Human	GC-QTOF-MS	OA=12, HC=20
2020 <sup>22</sup>				
Senol et al.,	Serum	Human	LC-QTOF-MS-MS	OKOA=14, NOKOA=14,
2019 <sup>23</sup>				HC=15

Pousinis et al.,	Plasma	Mouse	UHPLC-HR-MS	OA=8, HC=7
2020 <sup>24</sup>				
Zhang et al.,	Plasma	Human	TQ-UPLC-MS	DC-TKR=64, DC-
2016 <sup>25</sup>				NTKR=45,
				RC-TKR=72, RC-
				NTKR=76,
				LC-TKR=36, LC-
				NTKR=122
Tootsi et al.,	Serum	Human	UPLC-MS	OA=70, HC=82
2018 <sup>26</sup>				
Mickiewicz et	Synovial	Human	H <sup>1</sup> NMR, GC-MS	OA=55, HC=13
al., 2015 <sup>27</sup>	Fluid			
Mickiewicz et	Synovial	Ovine	H <sup>1</sup> NMR	OA=9, HC=9
al., 2015 <sup>28</sup>	Fluid			
Abdelrazig et	Urine	Human	LC-HR-MS	OA=74, HC=68
al., 2021 <sup>29</sup>				
Liu et al.,	Plasma	Human	UPLC-MS, FI-ESI-	n=610
202130			MS	
Yin et al.,	Urine	Rat	GC-MS	OA=8, HC=8
2017 <sup>31</sup>				
Zhang et al.,	Plasma	Human	TQ-UPLC-MS	DC-OA=64, DC-HC=45,
2016 <sup>32</sup>				RC-OA=72,
				RC-HC=76

Zhang et al.,	Synovial	Human	TQ-UPLC-MS	DC-OA=54, DC-HC=30,
2016 <sup>33</sup>	Fluid,			RC-OA=72,
	Plasma			RC-HC=71
Maerz et al.,	Serum	Rat	H <sup>1</sup> NMR, LC-MS-MS	OA=18, HC=18
2018 <sup>34</sup>				
Hu et al.,	Plasma	Human	TQ-UPLC-MS	DC-OA=64, DC-HC=45,
201635				RC-OA=72,
				RC-HC=76
Chen et al.,	Serum	Human	TQ-UPLC-MS	OA=32, HC=35
2018 <sup>36</sup>				
Zhai et al.,	Plasma	Human	TQ-UPLC-MS	OAup=57, OAnup=206,
2021 <sup>37</sup>				OAbp=177, OAnbp=116
Zhai et al.,	Serum	Human	LC-MS-MS	DC-OA=123, DC-
2010 <sup>38</sup>				HC=299,
				RC-OA=76, RC-HC=100
Zhang et al.,	Serum	Human	UPLC-MS	OA=40, HC=20
2015 <sup>39</sup>				
Kosinska et	Synovial	Human	FI-ESI-MS-MS, LC-	eOA=17, IOA=13, HC=9
al., 2014 <sup>40</sup>	Fluid		MS-MS	
Hügle et al.,	Synovial	Human	H <sup>1</sup> NMR	OA=15
201241	Fluid			
He et al.,	Plasma	Human	GC-MS	OA=12, HC=12
202142				
Li et al., 2009 <sup>43</sup>	Urine	Human	GC-MS	OA=37, HC=37

Table 2: General characteristics of each study include first author and date of publication, fluid sampled, model species, method of fluid analysis for metabolomics, and sample sizes. LC=Liquid chromatography, MS=Mass spectrometry, RP=Reversed phase, HPLC=Highperformance liquid chromatography, H<sup>1</sup>-NMR=Proton Nuclear Magnetic Resonance, ELISA=Enzyme-linked immunosorbent assay, FI-ESI=Flow-injection electrospray ionization, QTOF=quadrupole time-of-flight, GC=Gas chromatography, TOF=Time-of-flight, TQ=Triple quadrupole, HR=High resolution, UPLC=Ultra performance liquid chromatography, OA=Osteoarthritis subjects, HC=Healthy control for comparison, OA1=Evidence of OA progression on radiographic findings 18 months from baseline, OA2=No evidence of OA progression on radiographic findings 18 months from baseline, OA GI-II=OA grades I-II using Outerbridge scale scoring, OA GIII-IV=OA grades III-IV using Outerbridge scale scoring, OAm=Models with OA induced by meniscal destabilization (MD, 12) or anterior cruciate ligament transection (ACLT, 12), OKOA=Knee OA and obesity (BMI≥30), NOKOA=Knee OA without obesity (BMI<30), TKR=Total knee replacement, NTKR=No total knee replacement performed, DC=Discovery cohort subjects, RC=Replication cohort subjects, LC=Longitudinal study cohort subjects, OAup=OA patients with radiographic evidence of unilateral knee OA progression, OAnup=OA patients without radiographic evidence of unilateral knee OA progression, OAbp=OA patients with radiographic evidence of bilateral knee OA progression, OAnbp=OA patients without evidence of bilateral knee OA progression, eOA=OA with Outerbridge classification scale score ≤ 2, IOA=OA with Outerbridge classification scale score >2.

#### Risk of Bias in Studies

Bias was difficult to assess. In human studies, patient ethnicities were only reported in 2 of 36 articles. Potentially confounding concurrent health conditions were usually not determined or reported. Since obesity accompanies ~90% of knee OA cases, hypertension accompanies about 40% of knee OA cases, and diabetes accompanies about 16% of knee OA cases² this may impact patient metabolomic profiles. For selection of human control groups, patients were usually selected on the basis that they lacked a diagnosis of OA by a family medicine provider and/or lacked radiographic evidence of OA. However subclinical or asymptomatic forms of OA may be present in these HC groups, and this could potentially confound metabolomic comparisons. For human cases where body fluids were taken from live patients, controls were also matched for age, sex, and BMI to limit demographic variation between groups.

In animal models where OA was surgically induced, controls underwent sham surgeries in attempts to ensure that differences in metabolite profiles were a reflection of OA and not surgical complications (e.g. incision-related inflammation). The final source of bias occurs at the study level and involves the use of either targeted or untargeted metabolomics: both have limitations for analyzing the comprehensive body of metabolites present in a body fluid due to the large numbers of potential metabolites.

#### Synthesis of Results

For analysis, studies were grouped by body fluid; metabolites reported with statistical significance were extracted along with identified metabolic pathways, and are presented below.

#### <u>Urine</u>

Six studies evaluated metabolites found in urine, significant metabolites are summarized in **Table 3** below; three of these studies used humans as subjects, <sup>12,29,43</sup> two of the studies used Sprague-Dawley rats, <sup>18,31</sup> and one study used the Hartley outbread guinea pig model that spontaneously develops progressive knee OA starting at ~10 months of age<sup>10</sup>. No single metabolite was identified to be significantly altered across all 6 of the urine metabolite studies. Increased alanine concentrations in OA versus HC were identified in two studies with p-values <0.01.<sup>18,31</sup> Histidine was identified to be significantly altered in three studies; <sup>12,31,43</sup> two studies reported a statistically significant decrease in histidine concentrations between OA and HC with p-values <0.05.<sup>31,43</sup> Histidine levels were 1.3x higher (p-value 0.016) in OA patients with BMI ≥ 27kg/m² who had radiographic progression of knee OA at 18 months versus OA patients with BMI ≥ 27kg/m² who did not have radiographic progression of knee OA at 18 months versus OA patients with BMI ≥ 27kg/m² who did not have radiographic progression of knee OA at 18 months versus OA patients with on radiographic progression was defined as decrease in minimum joint space width on radiograph ≥0.7mm compared to baseline radiographs 18 months prior). Glutamine was found to be significantly decreased in three studies with p-value <0.05.<sup>18,31,43</sup>

The remaining significantly altered metabolites detected in the studies of urine mapped to many metabolic pathways. These include amino acid metabolism (phenylalanine, tryptophan, alanine, histidine, lysine, serine, threonine, glycine, glutamine, asparagine), lipid metabolism, nucleotide metabolism, the TCA cycle, ATP storage and utilization, and oxidative stress.

**Table 3:** Significant Metabolites Found in Urine

Author	Sample	Metabolites/Metabolic Pathways of Significance
	Model	
Smilde et	Guinea Pig	Acetate( $\uparrow$ ), Lactate( $\uparrow$ ), Glycine( $\uparrow$ ), Creatinine( $\downarrow$ ) in OA model
al., 2005 <sup>10</sup>		versus control

Loeser et	Human	Trigonelline( $\downarrow$ ) at both baseline and 18 months in patients with
al., 2016 <sup>12</sup>		radiographic OA progression versus OA patients without
		radiographic progression, Histidine(↑) at 18 months in OA
		patients with radiographic progression versus OA patients
		without radiographic progression.
Jiang et	Rat	Alanine( $\uparrow$ ), Alpha-Ketoglutarate( $\uparrow$ ), Homogentisic acid( $\uparrow$ ) in
al.,		OA versus HC
2018 <sup>18</sup>		Glutamine( $\downarrow$ ), aminomalonic acid( $\downarrow$ ), shikimic acid( $\downarrow$ ) in OA
		versus HC.
Abdelrazig	Human	TCA cycle metabolites(↑), Glutathione synthesis
et al.,		metabolites(↓), Metabolites of Tryptophan, Lysine, Serine, and
2021 <sup>29</sup>		Glycine metabolism(↓) in OA versus HC.
Yin et al.,	Rat	5-hydroxy indole acetic acid(↑), Alanine(↑), TCA cycle
2017 <sup>31</sup>		metabolites ( $\downarrow$ ), tryptophan( $\downarrow$ ),Glutamine( $\downarrow$ ) in OA versus HC.
Li et al.,	Human	TCA cycle metabolites( $\uparrow$ ), Histamine( $\uparrow$ ), Histidine( $\downarrow$ ),
201043		Glutamine(↓) in OA versus HC.

Key:  $(\uparrow)$  indicates an increase in concentration in OA compared to controls,  $(\downarrow)$  indicates a decrease in concentration in OA compared to controls.

# <u>Plasma</u>

13 studies evaluated OA metabolites found in plasma (Table 4). 10 studies evaluated plasma metabolites of OA in humans<sup>8,9,15,22,25,30,32,33,35,37,42</sup>, 2 studies evaluated plasma metabolites of OA in mice<sup>20,24</sup>. One study evaluated baseline plasma amino acid levels and was included for reference of absolute concentrations of plasma amino acids.<sup>9</sup> Ten of the 12 plasma metabolite studies found lysophosphatidylcholine (LysoPC) and phosphatidylcholine (PC) species to be statistically significantly altered in OA<sup>8,15,20,24,25,30,32,33,35,37</sup>. Among these 10 studies that reported

LysoPC and PC metabolism to be altered in OA, Rockel *et al* found LysoPC and PC signatures to be statistically significant only in males over the age of 50 years old compared to HC,<sup>8</sup> while Liu *et al* found LysoPC and PC levels to be statistically significant only between OA with multi-joint pain versus OA with single joint pain but not OA versus HC.<sup>30</sup>

Although some articles evaluated LysoPC and PC levels in OA overall, others found these two classes of molecules to be altered in various conditions and models. In addition to findings of altered plasma LysoPC and PC levels broadly in OA, LysoPC and PC levels were found to be altered in other settings; for example, altered LysoPC and PC levels compared to health control were seen in the context of metabolic changes in OA with high fat diets<sup>20</sup>, differential correlation networks for patient pain and function responses to total joint replacements<sup>15</sup>, progression of OA in either unilateral and/or bilateral knee OA<sup>37</sup>, or in OA associated with metabolic syndrome (MetS) or components of MetS<sup>33</sup>. While LysoPC and PC species were mentioned in these ten plasma metabolomics articles, there was not a clear consensus as to whether LysoPC and PC species were increased or decreased in OA plasma compared to HC.

Amino acid levels were also altered in many studies. However, as with LysoPC and PCs, increases or decreases were not always specified. Glutamine, isoleucine, proline, tryptophan, arginine, alanine, phenylalanine, serine, histidine, lysine, and asparagine were all reported to be significantly altered with p-values <0.05. 15,22,25,32,35,37

The remaining significantly altered metabolites corresponded largely to altered fatty acid metabolism, TCA cycle, and steroid biosynthesis.

Table 4: Significant Metabolites Found in Plasma

Author	Sample	Metabolites/Metabolic Pathways of Significance in OA vs
	Model	нс
Rockel et	Human	Lysophosphatidylcholine and phosphatidylcholine species were
al., 2018 <sup>8</sup>		found to be altered in OA versus healthy, strongest signature in
		males >50 years of age.
Steventon	Human	This study did not report metabolites, and instead was included
et al.,		as a reference as it reported normal plasma amino acid levels.
2012 <sup>9</sup>		
Costello et	Human	Glutamine, BCAAs, PCaaC38:0, and PCaaC40:6 found to
al., 2020 <sup>15</sup>		overlap most between OA patients without function or pain
		response after undergoing total knee replacement.
Datta et	Mouse	Lysophosphatidylcholine and phosphatidylcholine levels
al.,		remained elevated 3 months after returning to a normal chow
2017 <sup>20</sup>		diet from a high fat diet in OA mice model
Huang et	Human	Succinic acid( $\downarrow$ ), Xanthurenic acid( $\downarrow$ ), L-tryptophan( $\downarrow$ ) in OA
al., 2020 <sup>22</sup>		versus HC.
Pousinis	Mouse	Cholesteryl ester species(↑), phosphatidylcholine species(↑),
et al.,		Sphingomyelin d34:1(↑) in OA versus HC.
202024		
Zhang et	Human	Ratio of total lysophosphatidylcholines to total
al., 2016 <sup>25</sup>		phosphatidylcholines was on average 0.05μM higher in OA
		versus HC. Increased BCAA to histidine ratio seen in OA
		versus HC.
Liu et al.,	Human	Lysophosphatidylcholine and phosphatidylcholine metabolism
202130		was altered in OA patients with multi-joint pain versus OA

		patients with pain in one joint, however not significant when
		comparing OA versus HC.
Zhang et	Human	Arginine( $\downarrow$ ) Lysophosphatidylcholines species( $\downarrow$ ),
al., 2016 <sup>32</sup>		Phosphatidylcholine species( $\downarrow$ ), Proline( $\uparrow$ ) in OA versus HC.
Zhang et	Human	Altered phosphatidylcholine metabolism with
al., 2016 <sup>33</sup>		phosphatidylcholine species(↓) was shared between OA
		without diabetes and OA with diabetes and also found
		independently in OA and diabetes, although the link between
		these diseases and pathways is unknown. Separation between
		OA with MetS and OA with type II diabetes mellitus versus OA
		without MetS appeared to be due to type II diabetes as
		opposed to hypertension, dyslipidemia, or obesity in MetS.
Hu et al.,	Human	In differential correlation network, Ac-ornithine, Arginine,
2016 <sup>35</sup>		Alanine, and ornithine were found to be significant and made
		up the core of the network. Glycerophospholipids
		(lysophosphatidylcholine and phosphatidylcholine) species
		prominent in between the core and periphery of the network.
Zhai et al.,	Human	Phenylalanine was significantly associated with both unilateral
2021 <sup>37</sup>		and bilateral knee OA progression from baseline to 30-month
		follow-up, noted to be a better predictor in women. Arginine,
		Leucine, Isoleucine, and Carnitine species also associated with
		unilateral progression. Serine, Tryptophan, Histidine, Lysine,
		Ornithine, Asparagine, and Phosphatidylcholine species were
		associated with bilateral progression.

He et al.,	Human	Cholesterol( $\uparrow$ ), Stearic acid( $\uparrow$ ), L-Lactic acid( $\uparrow$ ), Alpha-
202142		Tocopherol(↑), Oxalic Acid(↑) in OA versus HC.

Key:  $(\uparrow)$  indicates an increase in concentration in OA compared to controls,  $(\downarrow)$  indicates a decrease in concentration in OA compared to controls.

#### Synovial Fluid

10 studies analyzed SF. Of these, 8 used a human model<sup>11,13,17,21,27,33,40,41</sup>, 1 used a New Zealand White rabbit model<sup>16</sup>, and 1 study used an ovine model<sup>28</sup> (**Table 5**). In the synovial fluid studies, many metabolites mapped to metabolic pathways involving fatty acids, phospholipids, amino acids, vitamins, TCA cycle, collagen breakdown, glycosaminoglycan and keratin sulfate degradation, urea cycle, and oxidative stress.

Phospholipid species were not only frequently found to be significantly altered between OA and controls,  $^{11,13,16,17,33,40}$  but phospholipid levels also continued to increase when comparing early OA disease (Outerbridge score  $\leq$  2) to late OA (Outerbridge score > 2) and the HC population.  $^{40}$ 

Metabolites indicating altered energy metabolism were also commonly identified in SF of OA compared to HC. These included FA metabolites, TCA cycle metabolites, gluconeogenic amino acids, and sugars in the synovial fluid samples. 11,13,16,17,21,27,28,41 Multiple carnitine species were perturbed; one study indicated decreased levels of two acylcarnitine species in OA synovial fluid. Two of the other studies mentioned altered acylcarnitine species as statistically significant OA predictors (e.g. AUC >0.90), although it was not clear if the particular acylcarnitine species increased or decreased in OA compared to HC. 11,16 Altered acylcarnitine levels in the SF of OA compared to HC may indicate altered energy production, as carnitine and

carnitine-acylcarnitine translocase allow acyl chains to move across the inner mitochondrial membrane and into the mitochondrial matrix where beta-oxidation occurs.<sup>44</sup>

The prominence of altered metabolites that are involved in mitochondrial energy production and metabolism, as well as evidence of oxidative stress, may indicate mitochondrial dysfunction in the osteoarthritic joint.

Table 5: Significant Metabolites Found in Synovial Fluid

Authors	Sample	Metabolites/Metabolic Pathways of Significance in OA vs
	Model	нс
Carlson et	Human	Phospholipid species, Fatty Acid metabolites, Acylcarnitine
al., 2018 <sup>11</sup>		species, Ursolic acid and Sulfonic acid derivatives were
		associated with differentiating OA versus HC.
Carlson et	Human	Altered extracellular matrix component metabolism
al., 2019 <sup>13</sup>		(glucosamine and galactosamine biosynthesis, ascorbate
		metabolism, keratin sulfate metabolism, N-glycan metabolism),
		amino acid metabolism, lipid metabolism (glycosphingolipid,
		glycerophospholipid, and carnitine/FA metabolism), leukotriene
		metabolism, central energy (glycolysis, gluconeogenesis, TCA
		cycle), oxidative stress (vitamin E and glutathione) and vitamin
		C, E, B1, B3, B6, and B9 metabolism in OA versus HC.
Hu et al.,	Rabbit	Polyamines (acetylspermidine species), Phospholipid species,
2020 <sup>16</sup>		Tryptophan and Tryptophan metabolites (including kynurenic
		acid), Acylcarnitine Species, Phenylalanine and Phenylalanine

		metabolites, Lysine, Arginine, and Histidine were associated
		with differentiating OA versus HC.
Kang et	Human	Tryptophan metabolism, arachidonic acid metabolism,
al.,		acylcarnitine metabolism, phospholipid metabolism,
2015 <sup>17</sup>		phenylalanine and tyrosine metabolism altered in OA.
Adams et	Human	IL-1Ra(↑), IL-6(↑), IL-8(↑), IL-10(↑), IL-15(↑), MCP-1(↑),
al.,		Tryptophan(↑), Kynurenine(↑), pro-hydroxy-proline(↑), FA
2014 <sup>21</sup>		species( $\uparrow$ ), Glutamate(>7x $\uparrow$ ), Glutathione metabolites( $\uparrow$ ),
		Isoleucine(↑) in post-traumatic ankle arthritis versus HC.
Mickiewicz	Human	Citrate( $\uparrow$ ), Malate( $\downarrow$ ), Acylcarnitine species( $\downarrow$ ), Creatine( $\downarrow$ ) in
et al.,		OA versus HC.
2015 <sup>27</sup>		
Mickiewicz	Ovine	Serine( $\downarrow$ ), Asparagine( $\downarrow$ ), Hydroxyproline( $\downarrow$ ), Uridine( $\downarrow$ ),
et al.,		Isobutyrate( $\uparrow$ ), and Glucose( $\uparrow$ ) reported as signs of early
2015 <sup>28</sup>		degenerative OA changes after surgical ACL-injury induced OA
		versus sham surgery HC.
Zhang et	Human	Altered phosphatidylcholine metabolism with
al., 2016 <sup>33</sup>		phosphatidylcholine species(↓) was shared between OA
		without diabetes and OA with diabetes and also found
		independently in OA and diabetes, although the link between
		these diseases and pathways is unknown. Separation between
		OA with MetS and OA with type II diabetes mellitus versus OA
		without MetS appeared to be due to type II diabetes as
		opposed to hypertension, dyslipidemia, or obesity in MetS.

Kosinska	Human	Sphingomyelin, Ceramide, Hexosylceramides, Phosphatidic
et al.,		Acid, Lysophosphatidic Acid, Phosphatidylglycerol, and
201440		Lysylphosphatidylglycerol species all increased in OA versus
		HC, and also increased between IOA compared to eOA.
Hügle et	Human	Hippuric acid, Phenylalanine, Tyrosine, D-Glucose, Valine,
al., 2012 <sup>41</sup>		TCA cycle metabolites, Carnitine species, Glutamine, Lactate,
		Alanine, and Lysine signatures present on H¹ NMR of OA.

Key:  $(\uparrow)$  indicates an increase in concentration in OA compared to controls,  $(\downarrow)$  indicates a decrease in concentration in OA compared to controls.

# Serum

8 studies involving serum were included in this review (**Table 6**): five articles analyzed human serum OA metabolites<sup>23,26,36,38,39</sup>, one article studied serum in rats<sup>34</sup>, one article examined serum in an ovine model<sup>19</sup>, and one article evaluated daily variation of acylcarnitines and amino acids in OA patients without comparison to a HC group<sup>14</sup>. Four of the articles reported altered levels of branched-chain amino acids between OA and HC groups.<sup>19,23,36,38</sup> Two studies reported statistically significant increases in valine, isoleucine, and leucine.<sup>36,38</sup> One study reported increased valine levels in OA serum.<sup>23</sup> The fourth article reported decreases in BCAAs in an ovine model of induced OA via surgical ACL transection.<sup>19</sup> Maher et al. suggest that their observed decrease in BCAAs may be specific to the ovine species, as literature reporting increased BCAAs present in human OA serum was reported prior to their publication<sup>38</sup> and has been replicated in other studies,<sup>23,36</sup> and therefore should be investigated further.<sup>19</sup>

Acylcarnitine species were serum metabolites associated with OA. One study found a lower ratio of total acylcarnitine to carnitine with lower levels of 8 out of 14 acylcarnitines species

measured in OA versus HC.<sup>26</sup> They also found lower levels of carnitine palmitoyltransferase 1 activity.<sup>26</sup> CPT-1 is present on the outer mitochondrial membrane and is the rate limiting enzyme for long-chain fatty acid beta-oxidation the mitochondrial matrix. Decreased activity of this enzyme may drive mitochondrial dysfunction in OA. Another study noted a decrease in acetyl-carnitine in OA compared to HC.<sup>36</sup> The fourth serum study to mention acylcarnitine species noted a significant increase in seven acylcarnitine species (p = 0.008-0.041) over 10 weeks after ACL rupture-induced post-traumatic OA.<sup>34</sup>

Other statistically significant serum metabolites mapped to phospholipid metabolism, amino acid metabolism (tryptophan, arginine, proline, serine, alanine, glycine, histidine, tyrosine), TCA cycle, nucleotide metabolism, energy metabolism, and the urea cycle.

**Table 6:** Significant Metabolites Found in Serum

Author	Sample	Metabolites/Metabolic Pathways of Significance in OA vs
	Model	нс
Thompson	Human	This study did not report metabolites, and instead was included
et al., 2011 <sup>14</sup>		as a reference as it reported daily variations of serum amino
		acid and acylcarnitine levels.
Maher et al.,	Ovine	BCAAs( $\downarrow$ ), 3-Methylhistidine( $\uparrow$ ), Glycine( $\uparrow$ ), Creatinine( $\uparrow$ ),
201219		Creatine(↑) at 4 weeks and 12 weeks in post-ACL Transection
		OA model versus HC.
Senol et al.,	Human	Phospholipid species( $\uparrow$ ), Indoleacetic acid( $\uparrow$ ), Urea( $\uparrow$ ),
2019 <sup>23</sup>		Valine( $\uparrow$ ), Alanine( $\uparrow$ ), FA metabolites( $\uparrow$ ) increased in OA
		versus Control.

Tootsi et al.,	Human	Total Acylcarnitine species to Carnitine species ratio was
2018 <sup>26</sup>		decreased in OA versus HC. Carnitine Palmitoyltransferase 1
		activity was decreased in OA versus HC.
Maerz et al.,	Rat	Acylcarnitine species increased at 72 hours, 4 weeks, and 10
2018 <sup>34</sup>		weeks post-ACL rupture OA model versus HC. Most
		significantly affected pathways in OA versus HC identified as
		cyanoamino acid metabolism, methane metabolism,
		sphingolipid metabolism, histidine metabolism, glutathione
		metabolism, tryptophan metabolism, beta-alanine metabolism,
		fructose and mannose metabolism, and amino and nucleotide
		sugar metabolism.
Chen et al.,	Human	BCAAs( $\uparrow$ ), Tryptophan( $\uparrow$ ), Alanine( $\uparrow$ ), 4-Hydroxy-L-Proline( $\uparrow$ ),
2018 <sup>36</sup>		Creatine( $\uparrow$ ), Arginine( $\uparrow$ ), Lysine( $\uparrow$ ), Tyrosine( $\uparrow$ ), Glutamine ( $\downarrow$ ),
		Phenylalanine(↓), Serine(↓), Proline(↓), Gamma-Aminobutyric
		Acid( $\downarrow$ ), Creatinine( $\downarrow$ ), Taurine( $\downarrow$ ), Asparagine( $\downarrow$ ), Acetyl-
		Carnitine(↓), Citrulline(↓) in OA versus HC.
Zhai et al.,	Human	Increased BCAA to Histidine ratio in OA versus HC, with ratio
2010 <sup>38</sup>		of Valine to Histidine and Isoleucine to Histidine having
		strongest statistical significance.
Zhang et al.,	Human	$CRP(\uparrow)$ , $Homocysteine(\uparrow)$ , $Tryptophan(\uparrow)$ , $Glycine(\downarrow)$ ,
2015 <sup>39</sup>		Histidine(↓) in OA versus HC.

Key: (↑) indicates an increase in concentration in OA compared to controls, (↓) indicates a decrease in concentration in OA compared to controls.

#### **Discussion**

Metabolomics is a growing field of research that can offer insight into disease pathophysiology and develop metabolic biomarkers that support early diagnosis and intervention, as well as both monitoring of disease progression and evaluation of treatment efficacy. OA is a disease with emerging metabolic features, and there are currently no treatment options that stop or reverse disease progression.<sup>45</sup> Therefore, identification and diagnosis of OA early in the disease course is critical to prevent extensive cartilage destruction and allow modifiable risk factors to be addressed to slow disease progression.

The studies included in this review analyzed the metabolomics of OA in urine, serum, plasma, and synovial fluid. The studies were done with humans, rats, mice, sheep, guinea pigs, and rabbits. Various analytical methods including mass spectrometry were performed to identify and compare metabolites between OA and comparison groups in each biological fluid. Metabolites that resulted from analysis of body fluids were either reported as being altered, while other studies further clarified whether the measured concentrations of reported metabolites were increased or decreased in comparison to control groups. In studies that reported increased or decreased concentrations, the data compiled by the authors shows that approximately 168 metabolites were increased in OA versus control out of 239 metabolites. This proportion was more or less consistent across each individual fluid sample.

In Maher et al<sup>19</sup>, the findings of decreased BCAA concentrations in ovine OA subjects is contrary to reported increases in BCAA concentrations in OA in other studies.<sup>23,36,38</sup> Maher et al suggest that their observation of decreased BCAA concentrations in OA may result from interspecies differences in disease metabolic processes. This highlights the need for further studies of OA metabolomics and pathophysiology, as well as further evaluation of animal models of OA. Identifying both similarities and differences between animal and human OA is

important to ensure that metabolomic findings are relatable across species. Biomarker candidates identified in animal models must be evaluated in human clinical populations to ensure their utility.

The heterogeneity of OA is reflected in the reported metabolites and pathways detailed in these studiers. From these studies, there was no consensus on either a single metabolite or a panel of metabolites that could serve as predictive biomarkers for early diagnosis of OA. This reflects the complexity of the disease and the multi-tissue pathophysiology that drive the progression of OA.

Although there was variation in the specific metabolites reported in these studies, common metabolic themes arose among many of the reports. Metabolites associated with mitochondrial dysfunction were detected in several studies. These include alterations in fatty acid metabolism, acylcarnitine and carnitine metabolites, and TCA cycle metabolites. Additionally several studies found metabolites indicating the presence of reactive oxygen species, gluconeogenic amino acid metabolites, and metabolites of antioxidants. There is potential for future studies to expand upon these results by focusing on metabolites associated with mitochondrial dysfunction.

Common themes seen across many studies include metabolism of phospholipids and articular cartilage, as well as metabolism of many amino acids, notably BCAAs. Altered levels of phospholipid metabolites including lysophosphatidylcholine and phosphatidylcholine species, sphingomyelins, ceramides, hexosylceramides, phosphatidylglycerols were noted; levels of proline and hydroxyproline, as well as glutamate which is used by mammals to synthesize proline, were noted in many studies and are major constituents of type II collagen found in articular cartilage. Altered amino acid metabolism was a common finding among many of the articles, with BCAA to histidine ratio being reported as a possible diagnostic marker of OA. Although the changes in the levels of BCAAs and histidine in the studies were not unanimously

agreed upon across the studies, it warrants further investigation and research as two studies claimed that BCAA to histidine ratio could be a statistically significant marker of OA. Due to their frequent recurrence across studies, metabolites of phospholipid and articular cartilage breakdown, as well amino acid metabolism, could be topics of further investigation in future studies.

#### Tryptophan Metabolism

Tryptophan can be synthesized and degraded through multiple pathways including the serotonin and melatonin pathway, the kynurenine pathway, and the indole pathway. Tryptophan metabolism and metabolite levels are altered in many diseases, ranging from chronic inflammatory diseases, autoimmune disorders, and neurodegenerative diseases. <sup>21</sup> 17 articles included in this review found tryptophan levels to be significantly altered in OA, and 5 articles suggested that the kynurenine pathway may be involved in OA pathogenesis in some way. Kynurenine is produced from tryptophan by indolamine-2,3-oxidase, and this kynurenine production is enhanced after treatment by either interferon gamma or tumor necrosis factoralpha. <sup>46,47</sup> Metabolites further downstream in the kynurenine pathway can lead to increased production of reactive oxygen species, as well as modulation of the inflammatory T-cell response to induce tolerance to mild inflammatory attack. <sup>46</sup> Further study of the tryptophankynurenine axis in OA may yield important information for better understanding OA pathogenesis.

#### Limitations

36 articles met the inclusion criteria for this review. However, there exists literature on the topic of metabolomics of OA that did not meet our inclusion criteria, or possibly were not displayed in the results of the database searches due to keyword or database limitations, and therefore were

not included in this review. As such this review focused on identifying basic metabolite features altered in OA, analyzing how metabolomic profiles change during OA disease progression, and finding relationships between OA and other health conditions like metabolic syndrome, orthopaedic trauma, and cardiovascular disease. The reviewed articles did not always report data on these other health conditions which limits the generalizability of these findings.

Additionally, Zhang *et al.*, 2016, reported metabolite ratios that were only significant in advanced knee OA but not in early-stage OA.<sup>25</sup> This suggests that metabolite biomarkers of OA may be stage-specific which suggests their potential to detect progression of OA.

Among all articles in this review, more than 350 metabolites were reported to be altered between OA and control subjects. These metabolites achieved varying degrees of significance with p-values smaller than 0.01 to barely distinguishable statistical differences between OA and HC. While some of these statistically significant metabolite findings were replicated across many studies,, such as LysoPC and PC species<sup>8,11,15,20,23-25,32,33,35,37</sup> and the amino acids glycine, <sup>10,19,29,39</sup> alanine, <sup>18,23,31,34-36,41</sup> and histidine, <sup>12,16,25,34,37-39,43</sup> and many others, a large majority of individual metabolites were not. However, because metabolic pathways involve detection of subsets of their individual metabolites, comparing reported metabolic pathways was more feasible than detailing individual metabolites in many cases. Thus, it is possible that future studies may identify additional biomarkers based on the pathways reported herein.

As plasma, urine, and serum are all fluids that reflect systemic metabolism, future studies should identify and control for confounding factors, such as concurrent medical conditions, patient demographics, and dietary habits. These key covariates may drive metabolomic changes that require additional statistical modeling for developing biomarkers of OA. Clinical sampling of SF for metabolomics involves inherent risks as it is an invasive procedure. This challenge renders obtaining HC samples challenging. For future studies of OA synovial fluid, it

would be beneficial to obtain healthy age- and sex-matched SF samples to allow for direct comparison to OA SF. Because SF directly contacts multiple tissues of the diseased joint, in contrast to systemic fluids, it contains great potential for developing biomarkers of OA and OA progression.

#### Conclusions

OA is a heterogenous disease with a wide range of altered metabolic pathways and processes that result in disease pathogenesis and progression. These studies demonstrate this heterogeneity through the vast array of metabolites and pathways reported. Through this review, metabolites indicated abnormalities in fatty acid metabolism and the TCA cycle suggesting mitochondrial dysfunction, altered energy metabolism, amino acid metabolism, nucleotide metabolism, phospholipid metabolism, urea cycle, and cartilage metabolism.

Many reports find differences in lysophosphatidylcholine/phosphatidylcholine metabolism, tryptophan and kynurenine metabolism, and branched-chain amino acid metabolism in OA. These metabolites and pathways have potential both for developing prognostic biomarkers of OA and for improved understanding of OA pathogenesis and progression. Sub-groups and endotypes of OA were also proposed in several reports. Future studies might characterize metabolomic differences between phenotypes and endotypes of OA. The identification of distinct phenotypes or endotypes may support development of novel therapeutic targets and help address modifiable risk factors involved in OA development and progression.

While metabolomic profiling is relatively new to the OA field, future primary and replication studies have good potential to provide reliable, sensitive, and specific panels of biomarkers to allow for early diagnosis of OA.

# **Acknowledgements**

The authors are grateful for funding support from NIH (NIAMS 5R01AR073964) and NSF (1554708 and 2140127).

# **Bibliography**

- 1. Osteoarthritis Action Alliance. OA Prevalence and Burden. Osteoarthritis Action Alliance. Accessed 8/23/2021, 2021. <a href="https://oaaction.unc.edu/oa-module/oa-prevalence-and-burden/">https://oaaction.unc.edu/oa-module/oa-prevalence-and-burden/</a>
- 2. Arthritis Foundation. *Arthritis by the Numbers*. 2021. Accessed 8/23/2021. <a href="https://www.arthritis.org/getmedia/e1256607-fa87-4593-aa8a-8db4f291072a/2019-abtn-final-march-2019.pdf">https://www.arthritis.org/getmedia/e1256607-fa87-4593-aa8a-8db4f291072a/2019-abtn-final-march-2019.pdf</a>
- 3. Arthritis Foundation. Osteoarthritis. Accessed 8/24/2021, 2021. <a href="https://www.arthritis.org/diseases/osteoarthritis">https://www.arthritis.org/diseases/osteoarthritis</a>
- 4. Goldring MB, Otero M. Inflammation in osteoarthritis. *Curr Opin Rheumatol*. Sep 2011;23(5):471-8. doi:10.1097/BOR.0b013e328349c2b1
- 5. Adams SB, Jr., Setton LA, Nettles DL. The role of metabolomics in osteoarthritis research. *J Am Acad Orthop Surg*. Jan 2013;21(1):63-4. doi:10.5435/jaaos-21-01-63
- 6. Jaggard MKJ, Boulangé CL, Akhbari P, et al. A systematic review of the small molecule studies of osteoarthritis using nuclear magnetic resonance and mass spectroscopy. *Osteoarthritis Cartilage*. Apr 2019;27(4):560-570. doi:10.1016/j.joca.2018.08.024
- 7. Harris JD, Quatman CE, Manring MM, Siston RA, Flanigan DC. How to write a systematic review. *Am J Sports Med*. Nov 2014;42(11):2761-8. doi:10.1177/0363546513497567
- 8. Rockel JS, Zhang W, Shestopaloff K, et al. A classification modeling approach for determining metabolite signatures in osteoarthritis. *PLoS One*. 2018;13(6):e0199618. doi:10.1371/journal.pone.0199618
- 9. Steventon GB, Mitchell SC, Angulo S, Barbas C. An investigation into possible xenobiotic-endobiotic inter-relationships involving the amino acid analogue drug, S-carboxymethyl-L-cysteine and plasma amino acids in humans. *Amino Acids*. May 2012;42(5):1967-1973. doi:10.1007/s00726-011-0926-y
- 10. Smilde AK, Jansen JJ, Hoefsloot HC, Lamers RJ, van der Greef J, Timmerman ME. ANOVA-simultaneous component analysis (ASCA): a new tool for analyzing designed metabolomics data. *Bioinformatics*. Jul 1 2005;21(13):3043-8. doi:10.1093/bioinformatics/bti476
- 11. Carlson AK, Rawle RA, Adams E, Greenwood MC, Bothner B, June RK. Application of global metabolomic profiling of synovial fluid for osteoarthritis biomarkers. *Biochemical and Biophysical Research Communications*. May 2018;499(2):182-188. doi:10.1016/j.bbrc.2018.03.117

- 12. Loeser RF, Pathmasiri W, Sumner SJ, et al. Association of urinary metabolites with radiographic progression of knee osteoarthritis in overweight and obese adults: an exploratory study. *Osteoarthritis Cartilage*. Aug 2016;24(8):1479-86. doi:10.1016/j.joca.2016.03.011
- 13. Carlson AK, Rawle RA, Wallace CW, et al. Characterization of synovial fluid metabolomic phenotypes of cartilage morphological changes associated with osteoarthritis. *Osteoarthritis and Cartilage*. Aug 2019;27(8):1174-1184. doi:10.1016/j.joca.2019.04.007
- 14. Thompson DK, Sloane R, Bain JR, et al. Daily variation of serum acylcarnitines and amino acids. *Metabolomics*. Aug 2012;8(4):556-565. doi:10.1007/s11306-011-0345-9
- 15. Costello CA, Hu T, Liu M, et al. Differential correlation network analysis identified novel metabolomics signatures for non-responders to total joint replacement in primary osteoarthritis patients. *Metabolomics*. Apr 2020;16(5)61. doi:10.1007/s11306-020-01683-1
- 16. Hu YW, Wu Q, Qiao Y, et al. Disturbances in Metabolic Pathways and the Identification of a Potential Biomarker Panel for Early Cartilage Degeneration in a Rabbit Anterior Cruciate Ligament Transection Model. *Cartilage*. 2020;1947603520921434. doi:10.1177/1947603520921434
- 17. Kang KY, Lee SH, Jung SM, Park SH, Jung BH, Ju JH. Downregulation of Tryptophan-related Metabolomic Profile in Rheumatoid Arthritis Synovial Fluid. *J Rheumatol.* Nov 2015;42(11):2003-11. doi:10.3899/jrheum.141505
- 18. Jiang H, Liu J, Qin XJ, et al. Gas chromatography-time of flight/mass spectrometry-based metabonomics of changes in the urinary metabolic profile in osteoarthritic rats. *Exp Ther Med*. Mar 2018;15(3):2777-2785. doi:10.3892/etm.2018.5788
- 19. Maher AD, Coles C, White J, et al. H-1 NMR Spectroscopy of Serum Reveals Unique Metabolic Fingerprints Associated with Subtypes of Surgically Induced Osteoarthritis in Sheep. *Journal of Proteome Research*. Aug 2012;11(8):4261-4268. doi:10.1021/pr300368h
- 20. Datta P, Zhang Y, Parousis A, et al. High-fat diet-induced acceleration of osteoarthritis is associated with a distinct and sustained plasma metabolite signature. *Sci Rep.* Aug 15 2017;7(1):8205. doi:10.1038/s41598-017-07963-6
- 21. Adams SB, Nettles DL, Jones LC, Miller SD, Guyton GP, Schon LC. Inflammatory Cytokines and Cellular Metabolites as Synovial Fluid Biomarkers of Posttraumatic Ankle Arthritis. *Foot & Ankle International*. Dec 2014;35(12):1241-1249. doi:10.1177/1071100714550652

- 22. Huang ZS, He ZR, Kong Y, Liu ZQ, Gong LZ. Insight into osteoarthritis through integrative analysis of metabolomics and transcriptomics. *Clinica Chimica Acta*. Nov 2020;510:323-329. doi:10.1016/j.cca.2020.07.010
- 23. Senol O, Gundogdu G, Gundogdu K, Miloglu FD. Investigation of the relationships between knee osteoarthritis and obesity via untargeted metabolomics analysis. *Clinical Rheumatology*. May 2019;38(5):1351-1360. doi:10.1007/s10067-019-04428-1
- 24. Pousinis P, Gowler PRW, Burston JJ, Ortori CA, Chapman V, Barrett DA. Lipidomic identification of plasma lipids associated with pain behaviour and pathology in a mouse model of osteoarthritis. *Metabolomics*. Feb 27 2020;16(3):32. doi:10.1007/s11306-020-01652-8
- 25. Zhang W, Sun G, Aitken D, et al. Lysophosphatidylcholines to phosphatidylcholines ratio predicts advanced knee osteoarthritis. *Rheumatology* (*Oxford*). Sep 2016;55(9):1566-74. doi:10.1093/rheumatology/kew207
- 26. Tootsi K, Kals J, Zilmer M, Paapstel K, Ottas A, Märtson A. Medium- and long-chain acylcarnitines are associated with osteoarthritis severity and arterial stiffness in end-stage osteoarthritis patients: a case-control study. *Int J Rheum Dis*. Jun 2018;21(6):1211-1218. doi:10.1111/1756-185x.13251
- 27. Mickiewicz B, Kelly JJ, Ludwig TE, et al. Metabolic analysis of knee synovial fluid as a potential diagnostic approach for osteoarthritis. *Journal of Orthopaedic Research*. Nov 2015;33(11):1631-1638. doi:10.1002/jor.22949
- 28. Mickiewicz B, Heard BJ, Chau JK, et al. Metabolic Profiling of Synovial Fluid in a Unilateral Ovine Model of Anterior Cruciate Ligament Reconstruction of the Knee Suggests Biomarkers for Early Osteoarthritis. *Journal of Orthopaedic Research*. Jan 2015;33(1):71-77. doi:10.1002/jor.22743
- 29. Abdelrazig S, Ortori CA, Doherty M, Valdes AM, Chapman V, Barrett DA. Metabolic signatures of osteoarthritis in urine using liquid chromatography-high resolution tandem mass spectrometry. *Metabolomics*. Mar 2021;17(3)29. doi:10.1007/s11306-021-01778-3
- 30. Liu M, Xie Z, Costello CA, et al. Metabolomic analysis coupled with extreme phenotype sampling identified that lysophosphatidylcholines are associated with multisite musculoskeletal pain. *Pain*. Feb 1 2021;162(2):600-608. doi:10.1097/j.pain.0000000000002052
- 31. Yin H, Wang L, Li QL, Zhang JH, Zhang L, Wang X. Metabolomic Analysis of Biochemical Changes in Urine of Osteoarthritis Rat and Interventional Effects of Bushen-Huoxue Herb Couple. *Chinese Herbal Medicines*. Oct 2017;9(4):369-375. doi:10.1016/s1674-6384(17)60117-5

- 32. Zhang W, Sun G, Likhodii S, et al. Metabolomic analysis of human plasma reveals that arginine is depleted in knee osteoarthritis patients. *Osteoarthritis Cartilage*. May 2016;24(5):827-34. doi:10.1016/j.joca.2015.12.004
- 33. Zhang WD, Sun G, Likhodii S, et al. Metabolomic analysis of human synovial fluid and plasma reveals that phosphatidylcholine metabolism is associated with both osteoarthritis and diabetes mellitus. *Metabolomics*. Feb 2016;12(2)24. doi:10.1007/s11306-015-0937-x
- 34. Maerz T, Sherman E, Newton M, et al. Metabolomic serum profiling after ACL injury in rats: A pilot study implicating inflammation and immune dysregulation in post-traumatic osteoarthritis. *J Orthop Res.* Jul 2018;36(7):1969-1979. doi:10.1002/jor.23854
- 35. Hu T, Zhang W, Fan Z, et al. METABOLOMICS DIFFERENTIAL CORRELATION NETWORK ANALYSIS OF OSTEOARTHRITIS. *Pac Symp Biocomput*. 2016;21:120-31.
- 36. Chen R, Han S, Liu XF, et al. Perturbations in amino acids and metabolic pathways in osteoarthritis patients determined by targeted metabolomics analysis. *Journal of Chromatography B-Analytical Technologies in the Biomedical and Life Sciences*. May 2018;1085:54-62. doi:10.1016/j.jchromb.2018.03.047
- 37. Zhai GJ, Sun XB, Randell EW, et al. Phenylalanine Is a Novel Marker for Radiographic Knee Osteoarthritis Progression: The MOST Study. *Journal of Rheumatology*. Jan 2021;48(1):123-128. doi:10.3899/jrheum.200054
- 38. Zhai G, Wang-Sattler R, Hart DJ, et al. Serum branched-chain amino acid to histidine ratio: a novel metabolomic biomarker of knee osteoarthritis. *Annals of the Rheumatic Diseases*. Jun 2010;69(6):1227-1231. doi:10.1136/ard.2009.120857
- 39. Zhang QM, Li H, Zhang ZD, Yang F, Chen JY. Serum Metabolites as Potential Biomarkers for Diagnosis of Knee Osteoarthritis. *Disease Markers*. 2015;2015684794. doi:10.1155/2015/684794
- 40. Kosinska MK, Liebisch G, Lochnit G, et al. Sphingolipids in human synovial fluida lipidomic study. *PLoS One*. 2014;9(3):e91769. doi:10.1371/journal.pone.0091769
- 41. Hügle T, Kovacs H, Heijnen IA, et al. Synovial fluid metabolomics in different forms of arthritis assessed by nuclear magnetic resonance spectroscopy. *Clin Exp Rheumatol*. Mar-Apr 2012;30(2):240-5.
- 42. He ZR, Liu ZQ, Gong LZ. Systematic evaluation of sample preparation strategy for GC-MS-based plasma metabolomics and its application in osteoarthritis. *Analytical Biochemistry*. May 2021;621114153. doi:10.1016/j.ab.2021.114153
- 43. Li X, Yang SB, Qiu YP, et al. Urinary metabolomics as a potentially novel diagnostic and stratification tool for knee osteoarthritis. *Metabolomics*. Mar 2010;6(1):109-118. doi:10.1007/s11306-009-0184-0

- 44. Talley JT. Biochemistry, Fatty Acid Oxidation. StatPearls; 2022. doi:NBK556002 Accessed 5/11/22. https://www.ncbi.nlm.nih.gov/pubmed/32310462
- 45. Mayo Clinic. Osteoarthritis. Accessed 8/31/2021, 2021. <a href="https://www.mayoclinic.org/diseases-conditions/osteoarthritis/symptoms-causes/syc-20351925">https://www.mayoclinic.org/diseases-conditions/osteoarthritis/symptoms-causes/syc-20351925</a>
- 46. Mándi Y, Vécsei L. The kynurenine system and immunoregulation. *J Neural Transm (Vienna*). Feb 2012;119(2):197-209. doi:10.1007/s00702-011-0681-y
- 47. Malone DG, Dolan PW, Brown RR, et al. Interferon gamma induced production of indoleamine 2,3 dioxygenase in cultured human synovial cells. *J Rheumatol*. Jun 1994;21(6):1011-9.